John Evans has been the CEO of Beam Therapeutics since January 2017, leading a company dedicated to developing innovative biotech solutions. With a strong background in biotechnology, he has played a significant role in advancing Beam's mission of providing life-long...

Current Market Cap

$2.08B

Number of Employees

436

Total Compensation

2021 - 2023

Trending down by -65.74% last year
Showing total compensation for the last 2021 - 2023

Stock

Down by -100.00% last year

Salary

Up by 5.38% last year

Bonus

Down by -3.78% last year

Other

Up by 49.53% last year

Year

2023

Total Compensation

$1.13M

Salary

$685.00K

Board Justification

The compensation philosophy is centered on pay for performance, aligning executive compensation with the achievement of corporate goals and stockholder value.

Bonus

$431.55K

Board Justification

Based on the achievement of corporate performance goals, resulting in a bonus of 105% of the target amount.

Other

$17.68K

Board Justification

Includes sabbatical payments, commuting benefits, 401(k) matching contributions, and a cell phone allowance.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and performance-based bonuses.

Performance Metrics

Performance metrics for 2023 included clinical, research and development, manufacturing, organizational, and financial goals.

SEC Filing

From April 19, 2024

John Evans

CEO of Beam Therapeutics

B

Education

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Born

Invalid Date - 0 years ago

Is Founder?

No

Current Tenure

3 years 10 months (Jan 2021 - Present)

Previous Experience

CEO of Beam Therapeutics Inc.

View Holdings

Insider Holdings of John Evans

BEAM

$29.99M

-$2.16M (-6.72%)

Last Insider Trade

BEAM

$1.47M

BEAM at $24.50/share

Jun 27, 2024

Sale